Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome

BackgroundPolycystic ovary syndrome (PCOS) is associated with increased risk of gestational diabetes mellitus (GDM), but reliable early predictive biomarkers remain lacking. This study investigated the predictive value of serum Sortilin, HMGB1, and galanin-like peptide (GALP) for GDM development in...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui Li, Xinghao Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1602622/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849734076204843008
author Hui Li
Xinghao Zhao
author_facet Hui Li
Xinghao Zhao
author_sort Hui Li
collection DOAJ
description BackgroundPolycystic ovary syndrome (PCOS) is associated with increased risk of gestational diabetes mellitus (GDM), but reliable early predictive biomarkers remain lacking. This study investigated the predictive value of serum Sortilin, HMGB1, and galanin-like peptide (GALP) for GDM development in PCOS pregnancies.MethodsThis prospective cohort study enrolled 139 PCOS patients. Serum Sortilin, HMGB1 and GALP levels were measured by ELISA at 8-12 weeks. GDM was diagnosed at 24-28 weeks using 75g OGTT (IADPSG criteria). Predictive performance was assessed using multivariable logistic regression and receiver operating characteristic (ROC) curve analysis, with adjustment for maternal age, BMI, and lipid profiles.ResultsThe PCOS-GDM group (n=60) showed significantly higher levels of all biomarkers versus controls (n=79) (all p<0.001). GALP (aOR=1.55, 95%CI:1.05-1.92) and HMGB1 (aOR=1.65, 95%CI:1.50-1.79) independently predicted GDM after adjustment. The combined model achieved superior prediction (AUC=0.84, 95%CI:0.74-0.94) versus individual markers.ConclusionSerum GALP and HMGB1 are promising early predictors of GDM in PCOS pregnancies, with combined assessment offering optimal risk stratification. These findings may facilitate timely intervention in high-risk populations.
format Article
id doaj-art-b25d3956e3924b7bbb243ab6bcb31fdb
institution DOAJ
issn 1664-2392
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-b25d3956e3924b7bbb243ab6bcb31fdb2025-08-20T03:07:54ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-05-011610.3389/fendo.2025.16026221602622Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndromeHui LiXinghao ZhaoBackgroundPolycystic ovary syndrome (PCOS) is associated with increased risk of gestational diabetes mellitus (GDM), but reliable early predictive biomarkers remain lacking. This study investigated the predictive value of serum Sortilin, HMGB1, and galanin-like peptide (GALP) for GDM development in PCOS pregnancies.MethodsThis prospective cohort study enrolled 139 PCOS patients. Serum Sortilin, HMGB1 and GALP levels were measured by ELISA at 8-12 weeks. GDM was diagnosed at 24-28 weeks using 75g OGTT (IADPSG criteria). Predictive performance was assessed using multivariable logistic regression and receiver operating characteristic (ROC) curve analysis, with adjustment for maternal age, BMI, and lipid profiles.ResultsThe PCOS-GDM group (n=60) showed significantly higher levels of all biomarkers versus controls (n=79) (all p<0.001). GALP (aOR=1.55, 95%CI:1.05-1.92) and HMGB1 (aOR=1.65, 95%CI:1.50-1.79) independently predicted GDM after adjustment. The combined model achieved superior prediction (AUC=0.84, 95%CI:0.74-0.94) versus individual markers.ConclusionSerum GALP and HMGB1 are promising early predictors of GDM in PCOS pregnancies, with combined assessment offering optimal risk stratification. These findings may facilitate timely intervention in high-risk populations.https://www.frontiersin.org/articles/10.3389/fendo.2025.1602622/fullpolycystic ovary syndromegestational diabetes mellitusbiomarkersHMGB1galanin-like peptide
spellingShingle Hui Li
Xinghao Zhao
Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome
Frontiers in Endocrinology
polycystic ovary syndrome
gestational diabetes mellitus
biomarkers
HMGB1
galanin-like peptide
title Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome
title_full Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome
title_fullStr Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome
title_full_unstemmed Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome
title_short Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome
title_sort predictive value of serum sortilin hmgb1 and galanin like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome
topic polycystic ovary syndrome
gestational diabetes mellitus
biomarkers
HMGB1
galanin-like peptide
url https://www.frontiersin.org/articles/10.3389/fendo.2025.1602622/full
work_keys_str_mv AT huili predictivevalueofserumsortilinhmgb1andgalaninlikepeptideforgestationaldiabetesmellitusinwomenwithpolycysticovarysyndrome
AT xinghaozhao predictivevalueofserumsortilinhmgb1andgalaninlikepeptideforgestationaldiabetesmellitusinwomenwithpolycysticovarysyndrome